Skip to main content
. 2022 Apr 20;89(6):761–772. doi: 10.1007/s00280-022-04428-0

Table 3.

Adverse events (AEs) and serious adverse events (SAEs) in propensity score-matched patients

Preferred term All patients (N = 2430) eGFR (mL/min/1.73 m2) p-value (AEs) p-value (SAEs)
AEs
n (%)
SAEs  < 60 (N = 1215) ≥ 60 (N = 1215)
AEs SAEs AEs SAEs
Any 2225 (91.6) 1413 (58.2) 1110 (91.4) 711 (58.5) 1115 (91.8) 702 (57.8) 0.7152 0.7113
Hand and foot skin reaction 1351 (55.6) 124 (5.1) 651 (53.6) 66 (5.4) 700 (57.6) 58 (4.8) 0.0454 0.4608
Hypertension 748 (30.8) 7 (0.3) 370 (30.5) 4 (0.3) 378 (31.1) 3 (0.3) 0.7252 0.7051
Rash 566 (23.3) 139 (5.7) 301 (24.8) 80 (6.6) 265 (21.8) 59 (4.9) 0.0840 0.0666
Diarrhoea 514 (21.2) 33 (1.4) 273 (22.5) 19 (1.6) 241 (19.8) 14 (1.2) 0.1119 0.3808
Hepatic dysfunction 508 (20.9) 270 (11.1) 261 (21.5) 126 (10.4) 247 (20.3) 144 (11.9) 0.4849 0.2453
Lipase/amylase increased 401 (16.5) 11 (0.5) 223 (18.4) 6 (0.5) 178 (14.7) 5 (0.4) 0.0139 0.7625
Dysphonia 106 (4.4) 1(0.0) 60 (4.9) 0 46 (3.8) 1 (0.1) 0.1644 0.3172
Alopecia 359 (14.8) 1 (0.0) 188 (15.5) 0 171 (14.1) 1 (0.1) 0.3311 0.3172
Cytopenia 273 (11.2) 92 (3.8) 136 (11.2) 44 (3.6) 137 (11.3) 48 (4.0) 0.9488 0.6707
Appetite decreased 254 (10.5) 44 (1.8) 138 (11.4) 27 (2.2) 116 (9.6) 17 (1.4) 0.1446 0.1282
Bleeding 189 (7.8) 159 (6.5) 104 (8.6) 84 (6.9) 85 (7.0) 75 (6.2) 0.1501 0.4603
Mucositis 159 (6.5) 8 (0.3) 82 (6.8) 5 (0.4) 77 (6.3) 3 (0.3) 0.6817 0.4788
Hypophosphatemia 158 (6.5) 3 (0.1) 84 (6.9) 2 (0.2) 74 (6.1) 1 (0.1) 0.4106 0.5635
Fever 152 (6.3) 42 (1.7) 78 (6.4) 22 (1.8) 74 (6.1) 20 (1.7) 0.7376 0.77556
Fatigue 49 (2.0) 5 (0.2) 24 (2.0) 3 (0.3) 25 (2.1) 2.0 (0.2) 0.8852 0.6544
Renal failure/dysfunction 45 (1.9) 26 (1.1) 38 (3.1) 20 (1.7) 7 (0.6) 6 (0.5)  < 0.0001 0.0058
Proteinuria or protein urine, n (%) 21 (0.9) 1 (0.0) 14 (1.2) 1 (0.1) 7 (0.6) 0 0.1250 0.3172